Bayesian Capital Management, LP Bio N Tech Se Transaction History

Bayesian Capital Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$90.91 - $112.75 $63,637 - $78,925	700 Added 11.29%	6,900 $728,000
Q3 2023 Nov 14, 2023	BUY	$98.5 - $125.08 $610,700 - $775,496	6,200 New	6,200 $673,000
Q4 2022 Feb 14, 2023	BUY	$118.43 - $186.05 $235,320 - $369,681	1,987 Added 23.62%	10,400 $1.56 Million
Q3 2022 Nov 14, 2022	SELL	$127.65 - $183.11 $394,055 - $565,260	-3,087 Reduced 26.84%	8,413 $1.14 Million
Q2 2022 Aug 15, 2022	BUY	$123.25 - $186.24 $788,800 - $1.19 Million	6,400 Added 125.49%	11,500 $1.72 Million
Q1 2022 May 16, 2022	BUY	$126.25 - $231.85 $459,171 - $843,238	3,637 Added 248.6%	5,100 $870,000
Q4 2021 Feb 14, 2022	SELL	$216.64 - $362.52 $1.26 Million - $2.12 Million	-5,837 Reduced 79.96%	1,463 $377,000
Q3 2021 Nov 15, 2021	BUY	$205.93 - $447.23 $1.5 Million - $3.26 Million	7,300 New	7,300 $1.99 Million
Q1 2021 May 14, 2021	SELL	$85.73 - $119.5 $831,581 - $1.16 Million	-9,700 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$72.71 - $129.54 $705,286 - $1.26 Million	9,700 New	9,700 $791,000

328

40.6M

845K

1.23M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $28.7B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Bayesian Capital Management, LP with notifications on news.